Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Cardiol Therapeutics Inc Class A (CRDL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/03/2025: CRDL (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $9.04
1 Year Target Price $9.04
| 1 | Strong Buy |
| 4 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 14.5% | Avg. Invested days 33 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 07/03/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 127.28M USD | Price to earnings Ratio - | 1Y Target Price 9.04 |
Price to earnings Ratio - | 1Y Target Price 9.04 | ||
Volume (30-day avg) 5 | Beta 0.76 | 52 Weeks Range 0.77 - 2.63 | Updated Date 07/5/2025 |
52 Weeks Range 0.77 - 2.63 | Updated Date 07/5/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.34 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -89.03% | Return on Equity (TTM) -190.11% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 107650320 | Price to Sales(TTM) 1069.35 |
Enterprise Value 107650320 | Price to Sales(TTM) 1069.35 | ||
Enterprise Value to Revenue 178.81 | Enterprise Value to EBITDA 0.3 | Shares Outstanding 82649696 | Shares Floating 79599950 |
Shares Outstanding 82649696 | Shares Floating 79599950 | ||
Percent Insiders 4.35 | Percent Institutions 10.26 |
Upturn AI SWOT
Cardiol Therapeutics Inc Class A
Company Overview
History and Background
Cardiol Therapeutics Inc. is a biotechnology company focused on the research and clinical development of pharmaceutical cannabidiol (CBD) and other anti-inflammatory therapies for the treatment of cardiovascular disease. Founded in 2016, it has progressed through pre-clinical and clinical stages, focusing on developing therapies for heart failure, acute myocarditis, and recurrent pericarditis.
Core Business Areas
- Pharmaceutical CBD Development: Focuses on developing pharmaceutically produced cannabidiol formulations for cardiovascular diseases.
- Cardiovascular Disease Therapies: Research and development of therapies targeting inflammation and fibrosis in heart conditions like heart failure and myocarditis.
Leadership and Structure
The company is led by a management team with expertise in pharmaceutical development and commercialization. The organizational structure includes research and development, clinical operations, and corporate functions.
Top Products and Market Share
Key Offerings
- CardiolRx: A pharmaceutically produced oral cannabidiol formulation. Currently undergoing clinical trials for acute myocarditis and recurrent pericarditis. Market share is currently zero, as the product is still in clinical development. Competitors include companies developing treatments for myocarditis and pericarditis using traditional pharmaceutical approaches, such as corticosteroids and colchicine.
Market Dynamics
Industry Overview
The cardiovascular disease market is large and growing, driven by aging populations and lifestyle factors. There's increasing interest in novel therapies that address unmet needs, particularly in inflammatory heart conditions.
Positioning
Cardiol Therapeutics is positioned as a specialty pharmaceutical company focused on developing CBD-based therapies for cardiovascular disease. Its competitive advantage lies in its pharmaceutical-grade CBD formulation and its focus on specific inflammatory heart conditions.
Total Addressable Market (TAM)
The TAM for cardiovascular disease therapies is estimated at hundreds of billions of dollars globally. Cardiol Therapeutics is positioned to address a segment of this market related to inflammatory heart conditions, which represents a significant opportunity.
Upturn SWOT Analysis
Strengths
- Proprietary pharmaceutical CBD formulation
- Focus on specific unmet needs in cardiovascular disease
- Experienced management team
- Strong intellectual property position
Weaknesses
- Limited revenue generation (clinical-stage company)
- Dependence on clinical trial success
- Relatively small market capitalization
- High cash burn rate
Opportunities
- Successful clinical trial results leading to regulatory approval
- Partnerships with larger pharmaceutical companies
- Expansion into new cardiovascular indications
- Increasing acceptance of CBD as a therapeutic agent
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established pharmaceutical companies
- Changes in the regulatory landscape for CBD products
- Generic competition if the CBD based medicine becomes accepted.
Competitors and Market Share
Key Competitors
- JNJ
- PFE
- BMY
Competitive Landscape
Cardiol Therapeutics competes with established pharmaceutical companies in the cardiovascular space, although its focus on CBD-based therapies differentiates it. Its smaller size and limited resources present challenges in competing with larger players.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by pre-clinical and clinical development milestones rather than revenue growth.
Future Projections: Future growth is dependent on successful clinical trial outcomes and potential commercialization of CardiolRx or other pipeline products. Analyst estimates vary widely depending on these factors.
Recent Initiatives: Recent initiatives include advancing clinical trials for CardiolRx in acute myocarditis and recurrent pericarditis, and exploring partnerships with other companies.
Summary
Cardiol Therapeutics is a clinical-stage biotechnology company with a focus on pharmaceutical CBD therapies for cardiovascular diseases. It has strong intellectual property and an experienced team but faces risks associated with clinical trial outcomes and competition from larger pharmaceutical companies. Success hinges on the approval and commercialization of CardiolRx or other pipeline products. The company needs to secure partnerships or additional funding to progress.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Financial data and market information are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Cardiol Therapeutics Inc Class A
Exchange NASDAQ | Headquaters Oakville, ON, Canada | ||
IPO Launch date 2019-01-15 | President, CEO & Director Mr. David G. Elsley MBA | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 18 | Website https://www.cardiolrx.com |
Full time employees 18 | Website https://www.cardiolrx.com | ||
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the developing of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.